XT
MLYS icon

XTX Topco’s Mineralys Therapeutics MLYS Stock Holding History

XTX Topco’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Sell
47,653
-20,754
-30% -$569K 0.02% 1554
2026
Q1 		$1.85M Sell
68,407
-5,271
-7% -$155K 0.03% 896
2025
Q4 		$2.67M Buy
73,678
+54,838
+291% +$2.2M 0.07% 395
2025
Q3 		$714K Buy
+18,840
New +$408K 0.04% 804
2025
Q2 		– Sell
-13,785
Closed -$219K – 2868
2025
Q1 		$219K Buy
+13,785
New +$159K 0.01% 1644
2024
Q2 		– Sell
-14,992
Closed -$194K – 2237
2024
Q1 		$194K Buy
+14,992
New +$185K 0.03% 1189
2023
Q4 		– Sell
-18,670
Closed -$178K – 1903
2023
Q3 		$178K Buy
+18,670
New +$243K 0.03% 1055

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

XTX Topco's MLYS Position: Q2 2026 in Review

XTX Topco reduced its Mineralys Therapeutics (MLYS) stake by 30% in Q2 2026, selling an estimated $569K and leaving 47,653 shares worth $1.29M. The position accounts for 0.02% of the portfolio, ranked #1554.

XTX Topco first reported a position in MLYS in Q3 2023 and has held it in 7 quarters since. The position peaked at $2.67M in Q4 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • XTX Topco held 47,653 shares of Mineralys Therapeutics worth $1.29M as of Q2 2026.
  • XTX Topco sold 20,754 Mineralys Therapeutics shares in Q2 2026, an estimated $569K.
  • Mineralys Therapeutics made up 0.02% of XTX Topco's portfolio in Q2 2026, its #1554 holding.
  • XTX Topco first reported a position in Mineralys Therapeutics in Q3 2023 and has held it in 7 quarters since.
  • XTX Topco's Mineralys Therapeutics position peaked at $2.67M in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.